MedTrace Logo

Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI

NCT04033861 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2023-06-01

No results posted yet for this study

Summary

The study intends to evaluate the efficacy of early rhBNP on myocardial remodeling and reperfusion in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention

Conditions

  • ST Segment Elevated Myocardial Infarction

Interventions

DRUG

rhBNP

rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.

DRUG

Control

saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • Shanghai Minhang Central Hospital

    collaborator OTHER

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    collaborator OTHER

  • Suqian First Hospital

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jun Pu, MD,PhD · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Univers

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2020-08-01
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04033861 on ClinicalTrials.gov